Skip to main content
. Author manuscript; available in PMC: 2009 May 12.
Published in final edited form as: Cell Host Microbe. 2008 Mar 13;3(3):158–167. doi: 10.1016/j.chom.2008.02.002

Figure 1.

Figure 1

Tat and nicotinamide cause T-cell hyperactivation

(A) Western blot analysis of Tat protein in Jurkat T cells infected with lentiviral vectors expressing LTR-GFP and LTR-Tat-GFP. Infected cultures were activated for 2 h and 8 h with α-CD3/28 antibodies.

(B) Real-time RT-PCR analysis of IL-2 mRNA levels in infected cultures 2 h after activation with α-CD3/28. Results are expressed as fold induction by α-CD3/28 treatment.

(C) IL-2 protein levels measured by ELISA in the supernatant of infected cultures 8 h after α-CD3/28 treatment.

(D) Real-time RT-PCR analysis of IL-2 mRNA levels in noninfected Jurkat T cells after treatment with nicotinamide and activation with α-CD3/28.

(E) Real-time RT-PCR analysis of IL-2 mRNA levels in Jurkat T cells infected with lentiviral vectors after treatment with nicotinamide and activation with α-CD3/28 antibodies.

(F) Western blot analysis of Tat protein in Jurkat T cells infected with lentiviral vectors after treatment with nicotinamide and activation with α-CD3/28. In B–E averages of three independent experiments (±SEM) are shown.